BillionToOne, Inc. (BLLN) fair value analysis
Nasdaq · Updated 2026-09-07
BillionToOne, Inc. is a healthcare company that develops and commercializes molecular diagnostic technologies designed to detect genetic abnormalities and diseases through advanced DNA sequencing and analysis methods. The company operates in the United States and serves healthcare providers and patients seeking non-invasive prenatal testing and other genetic screening solutions.
Valuation status
Awaiting full valuationBLLN does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $137.32
- Sector
- Healthcare
- 12-month range
- $77.49–$137.32
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- RSI zone
- Oversold
- 50/200-day trend
- Uptrend
- 52-week position
- The top quarter of its range
What our data shows for BLLN
- Shares are trading in the upper third of their 12-month price range of $77.49–$137.32.
- The 14-day relative strength index sits at an oversold 29.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for BLLN
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
What people are saying
Follow the BLLN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — TickrTrends' derived indicators for BLLN showed a shift in the Relative Strength Index this week, moving from the neutral zone into oversold territory. The stock's current valuation verdict remains awaiting full valuation. No other changes to derived indicators were reported this week.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is BLLN stock undervalued?
BLLN does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is BLLN's TickrTrends verdict?
BLLN is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is BLLN overbought or oversold?
BLLN's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.